Mota® SILVER
MotaBATHA 8/10 SILVER
Strain: Batha Balanced
A balanced THC and CBD profile. Commonly the starting point for cannabis-naive, older or anxiety-sensitive patients.
Specification
| Strain | Batha Balanced |
| THC | 8.3% |
| CBD | 10.6% |
| Type | Sativa-dominant |
| Irradiation | Non-irradiated |
| PDK / APA code | 5560041 |
| SÚKL code | 9190000 |
| Distributor | PHARMOS |
| Current batch | PB26002 |
| Expiry | 03/2028 |
Line
Mota® SILVER: THC above 5% and CBD above 5%.
Irradiation
This product is not irradiated. Microbiological limits are met without gamma treatment, which preserves the terpene profile the cultivar was selected for. The evidence.
Prescribing
Prescribed on eRecept under SÚKL code 9190000, created as a narcotic (NL) prescription. State the route of administration, the quantity in grams, and the exact THC and CBD percentages with the product name in the note field, for example:
THC 8.3% CBD 10.6% MotaBATHA 8/10 SILVER
Release
Released under EU-GMP in Czechia by Motagon’s Qualified Person. Batch number, certificate of analysis, expiry date and dispensing codes travel with the pack.
Other products
-
Mota® ROSE
MotaCHEESE 18/1 ROSE
A THC-dominant sativa-dominant cultivar. Commonly selected for patients with established tolerance, or where a balanced profile has not given sufficient relief.
Exodus Cheese
- THC / CBD
- 17.9% / 0.2%
- Type
- Sativa-dominant
- Irradiation
- Non-irradiated
- PDK / APA
- 5477709
-
Curaleaf
Curaleaf 24/1 WPT
A high-THC sativa-dominant cultivar from Curaleaf, distributed exclusively by Motagon in the Czech Republic.
Wedding Pop Triangle
- THC / CBD
- 23.8% / 0.05%
- Type
- Sativa-dominant
- Irradiation
- Irradiated
- PDK / APA
- 5567244
-
Curaleaf
Curaleaf 22/1 LC
A high-THC indica-dominant cultivar from Curaleaf, distributed exclusively by Motagon in the Czech Republic.
Lavender Cake
- THC / CBD
- 23.0% / 0.07%
- Type
- Indica-dominant
- Irradiation
- Irradiated
- PDK / APA
- 5567236
This page is intended for healthcare professionals. It is not advice on the treatment of an individual patient and does not replace national prescribing guidance or your own clinical judgement.